Global Gene Therapy for CNS Disorders Market Growth (Status and Outlook) 2023-2029

Global Gene Therapy for CNS Disorders Market Growth (Status and Outlook) 2023-2029

Gene Therapy is an experimental treatment that involves introducing genetic material into a person’s cells to fight or prevent disease. A gene can be delivered to a cell using a carrier known as a “vector.” The most common types of vectors used in gene therapy are viruses. The viruses used in gene therapy are altered to make them safe, although some risks still exist with gene therapy. The technology is still in its infancy.

LPI (LP Information)' newest research report, the “Gene Therapy for CNS Disorders Industry Forecast” looks at past sales and reviews total world Gene Therapy for CNS Disorders sales in 2022, providing a comprehensive analysis by region and market sector of projected Gene Therapy for CNS Disorders sales for 2023 through 2029. With Gene Therapy for CNS Disorders sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gene Therapy for CNS Disorders industry.

This Insight Report provides a comprehensive analysis of the global Gene Therapy for CNS Disorders landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Gene Therapy for CNS Disorders portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Gene Therapy for CNS Disorders market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gene Therapy for CNS Disorders and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gene Therapy for CNS Disorders.

The global Gene Therapy for CNS Disorders market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Gene Therapy for CNS Disorders is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Gene Therapy for CNS Disorders is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Gene Therapy for CNS Disorders is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Gene Therapy for CNS Disorders players cover Gilead (Kite Pharma), Amgen (BioVex), Novartis, Roche (Spark Therapeutics) and Bluebird Bio, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Gene Therapy for CNS Disorders market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Ex Vivo
In Vivo

Segmentation by application
Hospitals
Clinics
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Gilead (Kite Pharma)
Amgen (BioVex)
Novartis
Roche (Spark Therapeutics)
Bluebird Bio

Please note: The report will take approximately 2 business days to prepare and deliver.